Table Graph
      published meta-analysis   sensitivity analysis   studies

CanSino (Convidecia) in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias symptomatic Covid-19detailed resultsCanSino phase 3, 2021 0.43 [0.30; 0.60] 0.43[0.30; 0.60]CanSino phase 3, 202110%21,250NAnot evaluable ischemic strokedetailed resultsCanSino phase 2 (Zhu), 2020 0.33 [0.01; 16.67] 0.33[0.01; 16.67]CanSino phase 2 (Zhu), 202010%508NAnot evaluable Myocardial infarction detailed resultsCanSino phase 2 (Zhu), 2020 0.33 [0.01; 16.67] 0.33[0.01; 16.67]CanSino phase 2 (Zhu), 202010%508NAnot evaluable pulmonary embolismdetailed resultsCanSino phase 2 (Zhu), 2020 0.33 [0.01; 16.67] 0.33[0.01; 16.67]CanSino phase 2 (Zhu), 202010%508NAnot evaluable serious adverse events (SAE), anydetailed resultsCanSino phase 3, 2021 1.40 [0.62; 3.15] 1.40[0.62; 3.15]CanSino phase 3, 202110%36,717NAnot evaluable severe adverse eventsdetailed resultsCanSino phase 3, 2021 11.00 [1.42; 85.22] 11.00[1.42; 85.22]CanSino phase 3, 202110%36,717NAnot evaluable systemic adverse reaction, any, dose 1detailed resultsOut of scaleFengcai, 2021 20.24 [10.60; 38.63] 20.24[10.60; 38.63]Fengcai, 202110%430NAnot evaluable systemic adverse reaction, any, dose 2detailed resultsFengcai, 2021 4.39 [2.05; 9.41] 4.39[2.05; 9.41]Fengcai, 202110%430NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-04-30 13:36 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 760 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons